Results 111 to 120 of about 80,637 (252)

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

First-line treatment of metastatic melanoma: role of nivolumab

, 2017
Jeremy Force,1 April KS Salama,1,2 1Division of Hematology/Oncology, Duke University Medical Center, Durham, NC, USA; 2Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA Abstract: Historically, the median overall survival of ...
Force J, Salama AK
core  

Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer

Journal of Cancer Research and Practice
Nivolumab is now preferred as first-line and second-line treatment for advanced esophageal cancer, while regorafenib improves survival in refractory gastroesophageal cancer.
Mei-Chen Lin, Li-Yuan Bai, Shih-Peng Yeh, Chang-Fang Chiu, Ming-Yu Lien   +4 more
doaj   +1 more source

Nivolumab in melanoma

, 2016
: Introduction: The treatment of melanoma is evolving rapidly over the past few years. Areas covered: We conducted a comprehensive review of the literature on the role of nivolumab in melanoma Expert commentary: Nivolumab is approved by FDA and EMA for ...
Specenier, Pol
core  

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo, Wei‐Chen Tai, Yen‐Hao Chen, Ming‐Chao Tsai, Jing‐Houng Wang, Sheng‐Nan Lu, Tsung‐Hui Hu, Chao‐Hung Hung, Chien‐Hung Chen, Yuan‐Hung Kuo   +9 more
wiley   +1 more source

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

The Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell, Christopher Z. Wen, Vera Bzhilyanskaya, Jane Y. Tong, Adam C. Kaufman   +4 more
wiley   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

Med Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang, Huihui Yang, Guangxin Li, Guobang Liu, Zhulan Chen, Wenzhi Tian, Meiyang Huang, Xiaoling Liu, Yongsheng Zhao, Dong Chen   +9 more
wiley   +1 more source

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison

Frontiers in Oncology
BackgroundThe effectiveness of immune checkpoint inhibitors (ICIs) as adjuvant therapy for muscle-invasive urothelial carcinoma (MIUC) with high recurrence risk has been demonstrated.
Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii   +8 more
doaj   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Design, synthesis and activity evaluation of tetrahydroisoquinoline‐based programmed cell death ligand 1 inhibitors

Smart Molecules, EarlyView.
Based on a 3D‐quantitative structure‐activity relationship pharmacophore model, structural optimization of Y6 yielded Y7f. Mechanistic studies revealed that Y7f acted as a programmed death receptor 1/programmed cell death ligand 1 (PD‐L1) interaction inhibitor by inducing PD‐L1 dimerization. Y7f restored T‐cell function.
Menglin Yu, Sen Cai, Yanyan Pan, Heshuang Wang, Fengwu Zhang, Aiyu Ma, Shixuan Lv, Xiuhan Guo, Shisheng Wang, Qiling Song, Chunyan Ma, Shuai Wang, Li Zhang, Jian Wang, Qingwei Meng, Yueqing Li   +15 more
wiley   +1 more source